We’ve definitely had the creation of this vacuum in the second-line setting. And what should we be using now? Right now, the order of it is a little bit of dealer’s choice. So we have platinum doublet chemotherapy. We have biomarker-selected agents like erdafitinib for FGFR3 mutations. We have in HER2 for HER2-positive patients. We don’t know how to sequence them...
We’ve definitely had the creation of this vacuum in the second-line setting. And what should we be using now? Right now, the order of it is a little bit of dealer’s choice. So we have platinum doublet chemotherapy. We have biomarker-selected agents like erdafitinib for FGFR3 mutations. We have in HER2 for HER2-positive patients. We don’t know how to sequence them. I think it’s really important that for a lot of our patients who receive EV Pembro in the first-line setting, we’re going to be dealing with some degree of neuropathy left over from those patients. So how do we sequence these drugs like platinum thereafter and not exacerbate those problems that we have? So it’s space open to be ordered right now. I hope we can figure it out, but it’s the wild, wild west at the current time.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.